Nippon Chemiphar Co., Ltd. (4539) AI Stock Analysis

• Market Cap: ¥5.33B
• Dividend Yield: 3.38%
• Average Volume (3M): 2.47K
• Price to Earnings (P/E): 18.1
• Beta (1Y): 0.23
• Revenue Growth: 5.93%
• EPS Growth: N/A
• Country: JP
• Employees: 887
• Sector: Healthcare
• Sector Strength: 58
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 71.90
• Shares Outstanding: 4,261,420
• 10 Day Avg. Volume: 2,270
• 30 Day Avg. Volume: 2,466
• PEG Ratio: -0.38
• Price to Book (P/B): 0.36
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -3.44
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 70 Outperform
• Price Target: ¥1,626.00 ▲(10.09%Upside)

Nippon Chemiphar's overall stock score is driven primarily by its stable financial performance, despite cash flow challenges, and reasonable valuation with a moderate P/E ratio and attractive dividend yield. Technical analysis suggests a neutral to slightly positive outlook. The absence of recent earnings call or corporate event data limits additional insights.

Nippon Chemiphar Co., Ltd. Business Overview & Revenue Model

Company Description

Nippon Chemiphar Co., Ltd. is a Japan-based pharmaceutical company that focuses on the research, development, production, and distribution of pharmaceutical products. The company operates primarily in the healthcare sector, offering a range of generic drugs, ethical pharmaceuticals, and healthcare-related products. Nippon Chemiphar is committed to contributing to the health and quality of life of people around the world through innovative medication solutions.

How the Company Makes Money

Nippon Chemiphar Co., Ltd. generates revenue through the sale of its pharmaceutical products, with a significant portion coming from its generic drug offerings. The company benefits from the growing demand for cost-effective healthcare solutions, as generic drugs provide a more affordable alternative to brand-name medications. Additionally, Nippon Chemiphar invests in the research and development of new pharmaceutical products, which, upon successful commercialization, can contribute to its revenue streams. The company may also engage in partnerships and collaborations with other pharmaceutical firms, research institutions, and healthcare providers to enhance its product offerings and expand its market reach. These partnerships can result in shared revenues and access to new markets, further bolstering the company's financial performance.

Nippon Chemiphar Co., Ltd. Financial Statement Overview

Summary

Nippon Chemiphar's financial performance shows mixed results. The income statement indicates improved profitability, with margins recovering, but revenue growth remains inconsistent. The balance sheet is stable with a balanced leverage profile, but cash flow challenges persist with negative free cash flow and liquidity risks.

Income Statement

Nippon Chemiphar has shown inconsistent revenue growth with a 5.9% increase in the latest year after a decline in the previous year. The gross profit margin stands at 26.8%, which is moderate. However, the net profit margin has improved to 0.9% from a loss last year, indicating a positive turnaround in profitability. The EBITDA margin improved to 5.6%, showing healthier operational efficiency, but the EBIT margin remains low at 1.9%.

Balance Sheet

The company's debt-to-equity ratio of 0.94 indicates a balanced leverage profile. The return on equity is 1.5%, reflecting modest profitability relative to shareholder equity. The equity ratio of 38.5% suggests a solid capital structure, providing stability despite the modest ROE.

Cash Flow

The company faced a free cash flow deficit, although the negative growth rate has slightly improved from the previous year. The operating cash flow to net income ratio is negative due to operating cash flow being negative, indicating potential liquidity challenges. The free cash flow to net income ratio is also negative, signaling difficulties in converting profits into cash.

Breakdown
TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement		Total Revenue
31.99B	32.57B	30.75B	31.56B	32.51B	31.54B
	Gross Profit
8.38B	8.75B	7.74B	8.19B	9.07B	11.44B
	EBIT
-102.00M	607.00M	-494.00M	-241.00M	825.00M	564.00M
	EBITDA
1.40B	1.83B	1.40B	1.26B	2.41B	1.96B
	Net Income Common Stockholders
-249.00M	294.00M	-180.00M	339.00M	700.00M	495.00M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
9.39B	7.02B	9.20B	10.53B	11.64B	10.58B
	Total Assets
52.25B	49.85B	49.55B	48.57B	49.45B	47.12B
	Total Debt
19.04B	18.06B	16.98B	15.23B	14.79B	15.37B
	Net Debt
9.65B	11.04B	7.78B	4.70B	3.14B	4.78B
	Total Liabilities
33.77B	30.68B	31.09B	30.04B	30.95B	29.11B
	Stockholders Equity
18.47B	19.17B	18.46B	18.53B	18.50B	18.01B
Cash Flow		Free Cash Flow
0.00	-1.86B	-2.34B	-1.93B	1.07B	-85.00M
	Operating Cash Flow
0.00	-265.00M	296.00M	-916.00M	1.80B	1.50B
	Investing Cash Flow
0.00	-1.66B	-3.14B	-394.00M	35.00M	-1.02B
	Financing Cash Flow
0.00	-305.00M	1.45B	144.00M	-793.00M	29.00M

Nippon Chemiphar Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1477.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4539, the sentiment is Positive. The current price of 1477 is above the 20-day moving average (MA) of 1473.35, above the 50-day MA of 1468.20, and below the 200-day MA of 1479.23, indicating a neutral trend. The MACD of 1.49 indicates Positive momentum. The RSI at 50.84 is Neutral, neither overbought nor oversold. The STOCH value of 74.97 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4539.

Nippon Chemiphar Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4524	78 Outperform	¥8.65B	15.84		2.59%	2.90%	-21.60%
4569	73 Outperform	¥79.06B	9.38		0.67%	8.83%	70.61%
4539	70 Outperform	¥5.33B	18.11		3.38%	5.93%	―
4538	65 Neutral	¥18.78B	6.54		3.92%	9.31%	103.53%
Sector *	54 Neutral	$5.41B	3.27	-45.10%	3.29%	16.81%	0.02%
4582	51 Neutral	¥8.68B	―		―	-56.12%	-73.82%
4512	47 Neutral	¥10.55B	162.12		0.99%	0.66%	-40.86%